SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-019591
Filing Date
2023-05-24
Accepted
2023-05-24 16:09:39
Documents
14
Period of Report
2023-05-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20230524.htm   iXBRL 8-K 40126
2 EX-99.1 miratitherapeuticssitravat.htm EX-99.1 12867
6 miratilogoa.jpg GRAPHIC 18565
  Complete submission text file 0001628280-23-019591.txt   217825

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20230524.xsd EX-101.SCH 1897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20230524_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20230524_pre.xml EX-101.PRE 12508
8 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20230524_htm.xml XML 10554
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 23954213
SIC: 2834 Pharmaceutical Preparations